肺神经内分泌肿瘤诊疗进展
摘要
<正>2015年世界卫生组织(World Health Organization,WHO)发布第四版肺、胸膜、胸腺及心脏肿瘤分类,提出肺神经内分泌肿瘤(pulmonary neuroendocrine tumors,pN ETs)这一新的分类方法。该分类将小细胞肺癌(small cell lung cancer,SCLC)、肺大细胞神经内分泌癌(large cell neuroendocrine carcinoma,LCNEC)、肺类癌(pulmonary carcinoid,PC)和特发性弥漫性肺神经内分泌细胞增生(diffuse idiopathic pulmonary neuroendocrine cell hyperplasia,DIPNECH)统一归为
引文
[1]Filosso PL,Asamura H,Brunelli A,et al.Knowledge of pulmonary neuroendocrine tumors:where are we now?[J].Thoracic Surg Clin,2014,24:ix-xii.
[2]Gridelli C,Rossi A,Airoma G,et al.Treatment of pulmonary neuroendocrine tumours:state of the art and future developments[J].Cancer Treatment Rev,2013,39:466-472.
[3]Yao JC,Hassan M,Phan A,et al.One hundred years after“carcinoid”:epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J].J Clin Oncol,2008,26:3063-3072.
[4]依荷芭丽·迟,姜文昌,杜丰,等.神经内分泌瘤252例临床分析[J].中华肿瘤杂志,2013,35:67-70.
[5]Dincer HE,Podgaetz E,Andrade RS.Pulmonary neuroendocrine tumors:part I.spectrum and characteristics of tumors[J].JBronchol Interv Pulmonol,2015,22:267-273.
[6]Filosso PL,Rena O,Guerrera F,et al.Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma:a multicentre study on behalf of the European Association of Thoracic Surgeons(ESTS)neuroendocrine tumours of the lung working group[J].Eur J Cardiothorac Surg,2015,48:55-64.
[7]Modlin IM,Lye KD,Kidd M.A 5-decade analysis of 13,715carcinoid tumors[J].Cancer,2003,97:934-959.
[8]Bertino EM,Patricia D,Colonna JE,et al.Pulmonary neuroendocrine/carcinoid tumors:a review article[J].Cancer,2009,115:4434-4441.
[9]Hage R,de la Rivière AB,Seldenrijk CA,et al.Update in pulmonary carcinoid tumors:a review article[J].Ann Surg Oncol,2003,10:697-704.
[10]Davies SJ,Gosney JR,Hansell DM,et al.Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia:an under-recognised spectrum of disease[J].Thorax,2007,62:248-252.
[11]Wirtschafter E,Walts AE,Liu ST,et al.Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia of the lung(DIPNECH):current best evidence[J].Lung,2015,193:659-667.
[12]曹静,吕志排,党秋红,等.弥漫性特发性肺神经内分泌细胞增生12例临床病理分析[J].郑州大学学报(医学版),2015,50:716-717.
[13]Pelosi G,,Rindi G,Travis WD,et al.Ki-67 antigen in lung neuroendocrine tumors:unraveling a role in clinical practice[J].J Thorac Oncol,2014,9:273-284.
[14]Kee KM,Wang JH,Lee CM,et al.Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma:analysis of 5,613 cases from a medical center in southern Taiwan[J].Int J Cancer,2007,120:2650-2655.
[15]zaslan E,Bayram F,Karaca H,et al.Best prognostic factor of neuroendocrine tumors:grade or stage?A multidisciplinary single-center study[J].Turk J Gastroenterol,2016,27:509-514.
[16]Rindi G,Klersy C,Inzani F,et al.Grading the neuroendocrine tumors of the lung:an evidence-based proposal[J].Endocr Relat Cancer,2013,21:1-16.
[17]Grand B,Cazes A,Mordant P,et al.High grade neuroendocrine lung tumors:pathological characteristics,surgical management and prognostic implications[J].Lung Cancer,2013,81:404-409.
[18]Saji H,Tsuboi M,Matsubayashi J,et al.Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy[J].Anticancer Drugs,2010,21:89-93.
[19]Kenmotsu H,Niho S,Ito T,et al.A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma(large cell neuroendocrine carcinoma and small cell lung cancer)[J].Lung Cancer,2014,8:254-258.
[20]Gridelli C,Rossi A,Airoma G,et al.Treatment of pulmonary neuroendocrine tumours:state of the art and future developments[J].Cancer Treatment Reviews,2013,39:466-472.
[21]Lo Russo G,Pusceddu S,Proto C,et al.Treatment of lung large cell neuroendocrine carcinoma[J].Tumour Biol,2016,37:7047.
[22]Derks JL,Leblay N,Thunnissen E,et al.Molecular subtypes of pulmonary large cell neuroendocrine carcinoma predict chemotherapy treatment outcome[J].Clin Cancer Res,2018,24:33.
[23]Levra MG,Mazieres J,CA Valette,et al.Efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer:results from a French retrospective cohort[J].Thoracic Oncol,2017,12:707-012.
[24]Wang VE,Urisman A,Albacker L,et al.Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden[J].J Immunotherapy of Cancer,2017,5:75.
[25]Yendamuri S,Gold D,Jayaprakash V,et al.Is sublobar resection sufficient for carcinoid tumors?[J].Annals of Thoracic Surgery,2011,92:1778-1779.
[26]Steuer CE,Behera M,Kim S,et al.Atypical carcinoid tumor of the lung:a surveillance,epidemiology,and end results database analysis[J].J Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer,2015,10:479-485.
[27]Crona J,Fanola I,Lindholm DP,et al.Effect of temozolomide in patients with metastatic bronchial carcinoids[J].Neuroendocrinology,2013,98:151-155.
[28]Abdel-Rahman O,Fouad M.Temozolomide-based combination for advanced neuroendocrine neoplasms:a systematic review of the literature[J].Future Oncology,2015,11:1275-1290.
[29]Ianniello A,Sansovini M,Severi S,et al.Peptide receptor radionuclide therapy with(177)Lu-DOTATATE in advanced bronchial carcinoids:prognostic role of thyroid transcription factor 1and(18)F-FDG PET[J].Eur J Nucl Med Mol Imaging,2015,43:1040-1046.
[30]Fazio N,Granberg D,Grossman A,et al.Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors:analysis of the phase 3,randomized,placebo-controlled RADIANT-2study[J].Chest,2013,143:955-962.
[31]Yao JC,Fazio N,Singh S,et al.Everolimus for the treatment of advanced,non-functional neuroendocrine tumours of the lung or gastrointestinal tract(RADIANT-4):a randomised,placebocontrolled,phase 3study[J]Lancet,2016,387:968-977.
[32]Eichhorn F,Harms A,Warth A,et al.PD-L1 expression in large cell neuroendocrine carcinoma of the lung[J].Lung Cancer,2018,118:76-82.
[33]徐建明.重视对胃肠胰腺神经内分泌肿瘤的认识[J].中华肿瘤杂志,2012,34:158-160.
[2]Gridelli C,Rossi A,Airoma G,et al.Treatment of pulmonary neuroendocrine tumours:state of the art and future developments[J].Cancer Treatment Rev,2013,39:466-472.
[3]Yao JC,Hassan M,Phan A,et al.One hundred years after“carcinoid”:epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J].J Clin Oncol,2008,26:3063-3072.
[4]依荷芭丽·迟,姜文昌,杜丰,等.神经内分泌瘤252例临床分析[J].中华肿瘤杂志,2013,35:67-70.
[5]Dincer HE,Podgaetz E,Andrade RS.Pulmonary neuroendocrine tumors:part I.spectrum and characteristics of tumors[J].JBronchol Interv Pulmonol,2015,22:267-273.
[6]Filosso PL,Rena O,Guerrera F,et al.Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma:a multicentre study on behalf of the European Association of Thoracic Surgeons(ESTS)neuroendocrine tumours of the lung working group[J].Eur J Cardiothorac Surg,2015,48:55-64.
[7]Modlin IM,Lye KD,Kidd M.A 5-decade analysis of 13,715carcinoid tumors[J].Cancer,2003,97:934-959.
[8]Bertino EM,Patricia D,Colonna JE,et al.Pulmonary neuroendocrine/carcinoid tumors:a review article[J].Cancer,2009,115:4434-4441.
[9]Hage R,de la Rivière AB,Seldenrijk CA,et al.Update in pulmonary carcinoid tumors:a review article[J].Ann Surg Oncol,2003,10:697-704.
[10]Davies SJ,Gosney JR,Hansell DM,et al.Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia:an under-recognised spectrum of disease[J].Thorax,2007,62:248-252.
[11]Wirtschafter E,Walts AE,Liu ST,et al.Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia of the lung(DIPNECH):current best evidence[J].Lung,2015,193:659-667.
[12]曹静,吕志排,党秋红,等.弥漫性特发性肺神经内分泌细胞增生12例临床病理分析[J].郑州大学学报(医学版),2015,50:716-717.
[13]Pelosi G,,Rindi G,Travis WD,et al.Ki-67 antigen in lung neuroendocrine tumors:unraveling a role in clinical practice[J].J Thorac Oncol,2014,9:273-284.
[14]Kee KM,Wang JH,Lee CM,et al.Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma:analysis of 5,613 cases from a medical center in southern Taiwan[J].Int J Cancer,2007,120:2650-2655.
[15]zaslan E,Bayram F,Karaca H,et al.Best prognostic factor of neuroendocrine tumors:grade or stage?A multidisciplinary single-center study[J].Turk J Gastroenterol,2016,27:509-514.
[16]Rindi G,Klersy C,Inzani F,et al.Grading the neuroendocrine tumors of the lung:an evidence-based proposal[J].Endocr Relat Cancer,2013,21:1-16.
[17]Grand B,Cazes A,Mordant P,et al.High grade neuroendocrine lung tumors:pathological characteristics,surgical management and prognostic implications[J].Lung Cancer,2013,81:404-409.
[18]Saji H,Tsuboi M,Matsubayashi J,et al.Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy[J].Anticancer Drugs,2010,21:89-93.
[19]Kenmotsu H,Niho S,Ito T,et al.A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma(large cell neuroendocrine carcinoma and small cell lung cancer)[J].Lung Cancer,2014,8:254-258.
[20]Gridelli C,Rossi A,Airoma G,et al.Treatment of pulmonary neuroendocrine tumours:state of the art and future developments[J].Cancer Treatment Reviews,2013,39:466-472.
[21]Lo Russo G,Pusceddu S,Proto C,et al.Treatment of lung large cell neuroendocrine carcinoma[J].Tumour Biol,2016,37:7047.
[22]Derks JL,Leblay N,Thunnissen E,et al.Molecular subtypes of pulmonary large cell neuroendocrine carcinoma predict chemotherapy treatment outcome[J].Clin Cancer Res,2018,24:33.
[23]Levra MG,Mazieres J,CA Valette,et al.Efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer:results from a French retrospective cohort[J].Thoracic Oncol,2017,12:707-012.
[24]Wang VE,Urisman A,Albacker L,et al.Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden[J].J Immunotherapy of Cancer,2017,5:75.
[25]Yendamuri S,Gold D,Jayaprakash V,et al.Is sublobar resection sufficient for carcinoid tumors?[J].Annals of Thoracic Surgery,2011,92:1778-1779.
[26]Steuer CE,Behera M,Kim S,et al.Atypical carcinoid tumor of the lung:a surveillance,epidemiology,and end results database analysis[J].J Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer,2015,10:479-485.
[27]Crona J,Fanola I,Lindholm DP,et al.Effect of temozolomide in patients with metastatic bronchial carcinoids[J].Neuroendocrinology,2013,98:151-155.
[28]Abdel-Rahman O,Fouad M.Temozolomide-based combination for advanced neuroendocrine neoplasms:a systematic review of the literature[J].Future Oncology,2015,11:1275-1290.
[29]Ianniello A,Sansovini M,Severi S,et al.Peptide receptor radionuclide therapy with(177)Lu-DOTATATE in advanced bronchial carcinoids:prognostic role of thyroid transcription factor 1and(18)F-FDG PET[J].Eur J Nucl Med Mol Imaging,2015,43:1040-1046.
[30]Fazio N,Granberg D,Grossman A,et al.Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors:analysis of the phase 3,randomized,placebo-controlled RADIANT-2study[J].Chest,2013,143:955-962.
[31]Yao JC,Fazio N,Singh S,et al.Everolimus for the treatment of advanced,non-functional neuroendocrine tumours of the lung or gastrointestinal tract(RADIANT-4):a randomised,placebocontrolled,phase 3study[J]Lancet,2016,387:968-977.
[32]Eichhorn F,Harms A,Warth A,et al.PD-L1 expression in large cell neuroendocrine carcinoma of the lung[J].Lung Cancer,2018,118:76-82.
[33]徐建明.重视对胃肠胰腺神经内分泌肿瘤的认识[J].中华肿瘤杂志,2012,34:158-160.